Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P01589

UPID:
IL2RA_HUMAN

ALTERNATIVE NAMES:
TAC antigen; p55

ALTERNATIVE UPACC:
P01589; Q5W007

BACKGROUND:
The Interleukin-2 receptor subunit alpha, known alternatively as TAC antigen or p55, is integral to the immune system's balance. It binds interleukin-2, regulating the suppression of autoreactive T-cells by regulatory T cells (TREGs), thus playing a crucial role in immune tolerance.

THERAPEUTIC SIGNIFICANCE:
Linked to diseases such as Type 1 diabetes mellitus 10 and Immunodeficiency 41, which involve immune dysregulation and glucose homeostasis disorders, understanding the role of Interleukin-2 receptor subunit alpha could open doors to potential therapeutic strategies targeting these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.